Applied Therapeutics News Releases

Applied Therapeutics Reports Third Quarter 2022 Financial Results

NEW YORK, Nov. 09, 2022 (GLOBE NEWSWIRE) — Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high …

Applied Therapeutics Reports Second Quarter 2022 Financial Results

Completed public equity offering with gross proceeds of $30 million Granted orphan medicinal product designation by the EMA for AT-007 for treatment of Galactosemia Continued progress in three registrational Phase 3 trials in areas of high unmet medica…

Applied Therapeutics to Present at the UBS Global Healthcare Conference

NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) — Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical nee…

AT-007-1005 Clinical Study

Please fill out the form below to view information about AT-007, e.g. a list of contraindicated medications.
Name(Required)